{"count":2329,"next":"https://api-test.medunigraz.at/v1/research/project/?format=json&limit=20&offset=2020&ordering=-begin_effective","previous":"https://api-test.medunigraz.at/v1/research/project/?format=json&limit=20&offset=1980&ordering=-begin_effective","results":[{"id":1820,"title":{"de":"NANO-AS: Nano-Tox-Verlängerung","en":"NANO-AS: Nano-Tox-Verlängerung"},"short":"NANO-AS","url":null,"abstract":{"de":"The increasing incidence of cancer and of degenerative diseases, the latter increasingly in relatively young patientes, call for a new healthcare model that is more proactive, i.e. that detects disease pre-symptomatically when it is more amenable to treatment, more personalised, i.e. based on the growing knowledge about the molecular mechanisms underlying disease, less traumatic and more targeted, i.e. that non-invasively or minimally invasively and specifically treats the affected tissue or organ(s) and allows more informed interventions, i.e. That enables the progress of therapy and relapse to be followed in as close to real time as possible.\r\nThe extended project will build on the achievements of NANO-HEALTH made to date. Within the first two years an NP platform based on 4 different types of NPs was elaborated and optimised for drug delivery and imaging. All NPs were characterised in detail by physico-chemical and chemical methods. Starting from this platform, the most promising NPs were optimised for oral drug delivery, for a depot formulation of Vasoactive Intestinal Peptide (VIP), for contrast media using MRI and Spect/PET and to trace stem cells in vivo and for the early detection of atherosclerotic plaque. Several proof-of-concept studies were performed from the end of year 2 up to now (3 years and 3 months).\r\n\r\nThe prolongation of NANO-HEALTH year 5 to 7 will build on the work done to date to develop new NM-based solutions for targeted drug delivery and imaging. The following topics will be pursued:\r\n*Further development of thiomers for oral and topical (depot)delivery of active substances\r\n*(Based on the successful results obtained so far) large scale production processes for nano-thiomers and PLA-HSA-based NPs\r\n*Development of targeted imaging for cancer using MRI\r\n*Stem cell tracking in vivo\r\n*Atherosclerotic plaque detection\r\n*Chronic nanotoxicity","en":"The increasing incidence of cancer and of degenerative diseases, the latter increasingly in relatively young patientes, call for a new healthcare model that is more proactive, i.e. that detects disease pre-symptomatically when it is more amenable to treatment, more personalised, i.e. based on the growing knowledge about the molecular mechanisms underlying disease, less traumatic and more targeted, i.e. that non-invasively or minimally invasively and specifically treats the affected tissue or organ(s) and allows more informed interventions, i.e. That enables the progress of therapy and relapse to be followed in as close to real time as possible.\r\nThe extended project will build on the achievements of NANO-HEALTH made to date. Within the first two years an NP platform based on 4 different types of NPs was elaborated and optimised for drug delivery and imaging. All NPs were characterised in detail by physico-chemical and chemical methods. Starting from this platform, the most promising NPs were optimised for oral drug delivery, for a depot formulation of Vasoactive Intestinal Peptide (VIP), for contrast media using MRI and Spect/PET and to trace stem cells in vivo and for the early detection of atherosclerotic plaque. Several proof-of-concept studies were performed from the end of year 2 up to now (3 years and 3 months).\r\n\r\nThe prolongation of NANO-HEALTH year 5 to 7 will build on the work done to date to develop new NM-based solutions for targeted drug delivery and imaging. The following topics will be pursued:\r\n*Further development of thiomers for oral and topical (depot)delivery of active substances\r\n*(Based on the successful results obtained so far) large scale production processes for nano-thiomers and PLA-HSA-based NPs\r\n*Development of targeted imaging for cancer using MRI\r\n*Stem cell tracking in vivo\r\n*Atherosclerotic plaque detection\r\n*Chronic nanotoxicity"},"begin_planned":"2009-03-01T01:00:00+01:00","begin_effective":"2009-03-01T01:00:00+01:00","end_planned":"2012-02-28T01:00:00+01:00","end_effective":"2012-02-28T01:00:00+01:00","assignment":"2009-05-18T12:36:34+02:00","program":null,"subprogram":"Nano-Health","organization":28394,"category":10,"type":10,"partner_function":2,"manager":53900,"contact":53900,"status":2,"research":1,"grant":10,"event":null,"study":null,"language":null,"funders":[416],"funder_projectcode":null,"ethics_committee":null,"edudract_number":null,"persons":["1820-53900-10"]},{"id":1821,"title":{"de":"Nano-Health: Nano-Plaque-Extension","en":"Nano-Health: Nano-Plaque-Extension"},"short":"Nano-Plaque-Extension","url":null,"abstract":{"de":"The increasing incidence of cancer and of degenerative diseases, the latter increasingly in relatively young patientes, call for a new healthcare model that is more proactive, i.e. that detects disease pre-symptomatically when it is more amenable to treatment, more personalised, i.e. based on the growing knowledge about the molecular mechanisms underlying disease, less traumatic and more targeted, i.e. that non-invasively or minimally invasively and specifically treats the affected tissue or organ(s) and allows more informed interventions, i.e. That enables the progress of therapy and relapse to be followed in as close to real time as possible.\r\nThe extended project will build on the achievements of NANO-HEALTH made to date. Within the first two years an NP platform based on 4 different types of NPs was elaborated and optimised for drug delivery and imaging. All NPs were characterised in detail by physico-chemical and chemical methods. Starting from this platform, the most promising NPs were optimised for oral drug delivery, for a depot formulation of Vasoactive Intestinal Peptide (VIP), for contrast media using MRI and Spect/PET and to trace stem cells in vivo and for the early detection of atherosclerotic plaque. Several proof-of-concept studies were performed from the end of year 2 up to now (3 years and 3 months).\r\n\r\nThe prolongation of NANO-HEALTH year 5 to 7 will build on the work done to date to develop new NM-based solutions for targeted drug delivery and imaging. The following topics will be pursued:\r\n*Further development of thiomers for oral and topical (depot)delivery of active substances\r\n*(Based on the successful results obtained so far) large scale production processes for nano-thiomers and PLA-HSA-based NPs\r\n*Development of targeted imaging for cancer using MRI\r\n*Stem cell tracking in vivo\r\n*Atherosclerotic plaque detection\r\n*Chronic nanotoxicity","en":"The increasing incidence of cancer and of degenerative diseases, the latter increasingly in relatively young patientes, call for a new healthcare model that is more proactive, i.e. that detects disease pre-symptomatically when it is more amenable to treatment, more personalised, i.e. based on the growing knowledge about the molecular mechanisms underlying disease, less traumatic and more targeted, i.e. that non-invasively or minimally invasively and specifically treats the affected tissue or organ(s) and allows more informed interventions, i.e. That enables the progress of therapy and relapse to be followed in as close to real time as possible.\r\nThe extended project will build on the achievements of NANO-HEALTH made to date. Within the first two years an NP platform based on 4 different types of NPs was elaborated and optimised for drug delivery and imaging. All NPs were characterised in detail by physico-chemical and chemical methods. Starting from this platform, the most promising NPs were optimised for oral drug delivery, for a depot formulation of Vasoactive Intestinal Peptide (VIP), for contrast media using MRI and Spect/PET and to trace stem cells in vivo and for the early detection of atherosclerotic plaque. Several proof-of-concept studies were performed from the end of year 2 up to now (3 years and 3 months).\r\n\r\nThe prolongation of NANO-HEALTH year 5 to 7 will build on the work done to date to develop new NM-based solutions for targeted drug delivery and imaging. The following topics will be pursued:\r\n*Further development of thiomers for oral and topical (depot)delivery of active substances\r\n*(Based on the successful results obtained so far) large scale production processes for nano-thiomers and PLA-HSA-based NPs\r\n*Development of targeted imaging for cancer using MRI\r\n*Stem cell tracking in vivo\r\n*Atherosclerotic plaque detection\r\n*Chronic nanotoxicity"},"begin_planned":"2009-03-01T01:00:00+01:00","begin_effective":"2009-03-01T01:00:00+01:00","end_planned":"2012-01-28T01:00:00+01:00","end_effective":"2012-02-28T01:00:00+01:00","assignment":"2009-05-18T13:05:25+02:00","program":null,"subprogram":"Nano-Health Verlängerung","organization":14028,"category":10,"type":10,"partner_function":2,"manager":52854,"contact":52854,"status":2,"research":3,"grant":10,"event":null,"study":null,"language":null,"funders":[416],"funder_projectcode":null,"ethics_committee":null,"edudract_number":null,"persons":["1821-52854-10"]},{"id":1819,"title":{"de":"Nano-Health: 4D Molecular Imaging of human Stem Cells in vivo","en":"Nano-Health: 4D Molecular Imaging of human Stem Cells in vivo"},"short":"Nano-Health: 4D Imaging of Stem Cells","url":null,"abstract":{"de":"The increasing incidence of cancer and of degenerative diseases, the latter increasingly in relatively young patientes, call for a new healthcare model that is more proactive, i.e. that detects disease pre-symptomatically when it is more amenable to treatment, more personalised, i.e. based on the growing knowledge about the molecular mechanisms underlying disease, less traumatic and more targeted, i.e. that non-invasively or minimally invasively and specifically treats the affected tissue or organ(s) and allows more informed interventions, i.e. That enables the progress of therapy and relapse to be followed in as close to real time as possible.\r\nThe extended project will build on the achievements of NANO-HEALTH made to date. Within the first two years an NP platform based on 4 different types of NPs was elaborated and optimised for drug delivery and imaging. All NPs were characterised in detail by physico-chemical and chemical methods. Starting from this platform, the most promising NPs were optimised for oral drug delivery, for a depot formulation of Vasoactive Intestinal Peptide (VIP), for contrast media using MRI and Spect/PET and to trace stem cells in vivo and for the early detection of atherosclerotic plaque. Several proof-of-concept studies were performed from the end of year 2 up to now (3 years and 3 months).\r\n\r\nThe prolongation of NANO-HEALTH year 5 to 7 will build on the work done to date to develop new NM-based solutions for targeted drug delivery and imaging. The following topics will be pursued:\r\n*Further development of thiomers for oral and topical (depot)delivery of active substances\r\n*(Based on the successful results obtained so far) large scale production processes for nano-thiomers and PLA-HSA-based NPs\r\n*Development of targeted imaging for cancer using MRI\r\n*Stem cell tracking in vivo\r\n*Atherosclerotic plaque detection\r\n*Chronic nanotoxicity","en":"The increasing incidence of cancer and of degenerative diseases, the latter increasingly in relatively young patientes, call for a new healthcare model that is more proactive, i.e. that detects disease pre-symptomatically when it is more amenable to treatment, more personalised, i.e. based on the growing knowledge about the molecular mechanisms underlying disease, less traumatic and more targeted, i.e. that non-invasively or minimally invasively and specifically treats the affected tissue or organ(s) and allows more informed interventions, i.e. That enables the progress of therapy and relapse to be followed in as close to real time as possible.\r\nThe extended project will build on the achievements of NANO-HEALTH made to date. Within the first two years an NP platform based on 4 different types of NPs was elaborated and optimised for drug delivery and imaging. All NPs were characterised in detail by physico-chemical and chemical methods. Starting from this platform, the most promising NPs were optimised for oral drug delivery, for a depot formulation of Vasoactive Intestinal Peptide (VIP), for contrast media using MRI and Spect/PET and to trace stem cells in vivo and for the early detection of atherosclerotic plaque. Several proof-of-concept studies were performed from the end of year 2 up to now (3 years and 3 months).\r\n\r\nThe prolongation of NANO-HEALTH year 5 to 7 will build on the work done to date to develop new NM-based solutions for targeted drug delivery and imaging. The following topics will be pursued:\r\n*Further development of thiomers for oral and topical (depot)delivery of active substances\r\n*(Based on the successful results obtained so far) large scale production processes for nano-thiomers and PLA-HSA-based NPs\r\n*Development of targeted imaging for cancer using MRI\r\n*Stem cell tracking in vivo\r\n*Atherosclerotic plaque detection\r\n*Chronic nanotoxicity"},"begin_planned":"2009-03-01T01:00:00+01:00","begin_effective":"2009-03-01T01:00:00+01:00","end_planned":"2012-02-28T01:00:00+01:00","end_effective":"2012-02-28T01:00:00+01:00","assignment":"2009-05-18T11:50:29+02:00","program":null,"subprogram":"Nano-Health","organization":14082,"category":10,"type":10,"partner_function":2,"manager":null,"contact":null,"status":2,"research":3,"grant":10,"event":null,"study":null,"language":null,"funders":[416],"funder_projectcode":null,"ethics_committee":null,"edudract_number":null,"persons":["1819-50747-12"]},{"id":1716,"title":{"de":"Nano-Health: Nano-structured materials for drug targeting, release and imaging","en":"Nano-Health: Nano-structured materials for drug targeting, release and imaging"},"short":"NANO-HEALTH","url":null,"abstract":{"de":"The increasing incidence of cancer and of degenerative diseases, the latter uncreasingly in relatively young patients, calls for a new healthcare model that is more proactive (detects asymptomatic disease when it is more amenable to treatment), more personalised (based on the growing knowledge about the molecular mechanisms underlying disease), less traumatic and more targeted (non/minimally invasively and specifically treats the affected tissue or organ(s)) and that allows more informed interventions (following of the progress of therapy and disease reoccurrence in as close to real time as possible).\r\nThis prolongation of NANO-HEALTH will build on the work done to date to develop new NM-based solutions for targeted drug delivery and imaging. The following topics will be pursued:\r\n*Further development of thiomers for oral delivery of active substances\r\n*An industrial production process for nano-thiomers\r\n*Development of targeted imaging for cancer using MRI\r\n*Stem cell tracking in vivo\r\n*Atherosclerotic plaque detection\r\n*Chronic nanotoxicity","en":"The increasing incidence of cancer and of degenerative diseases, the latter uncreasingly in relatively young patients, calls for a new healthcare model that is more proactive (detects asymptomatic disease when it is more amenable to treatment), more personalised (based on the growing knowledge about the molecular mechanisms underlying disease), less traumatic and more targeted (non/minimally invasively and specifically treats the affected tissue or organ(s)) and that allows more informed interventions (following of the progress of therapy and disease reoccurrence in as close to real time as possible).\r\nThis prolongation of NANO-HEALTH will build on the work done to date to develop new NM-based solutions for targeted drug delivery and imaging. The following topics will be pursued:\r\n*Further development of thiomers for oral delivery of active substances\r\n*An industrial production process for nano-thiomers\r\n*Development of targeted imaging for cancer using MRI\r\n*Stem cell tracking in vivo\r\n*Atherosclerotic plaque detection\r\n*Chronic nanotoxicity"},"begin_planned":"2009-01-01T01:00:00+01:00","begin_effective":"2009-03-01T01:00:00+01:00","end_planned":"2011-12-31T01:00:00+01:00","end_effective":"2012-02-28T01:00:00+01:00","assignment":"2009-01-14T14:15:30+01:00","program":null,"subprogram":"Nano-Initiative","organization":28392,"category":10,"type":10,"partner_function":2,"manager":54033,"contact":null,"status":2,"research":5,"grant":10,"event":null,"study":null,"language":null,"funders":[416],"funder_projectcode":null,"ethics_committee":null,"edudract_number":null,"persons":["1716-54033-10"]},{"id":1735,"title":{"de":"GOLD3 - Genomics Of Lipid Droplet Biology, Component 8: Lipid droplet-associated proteins regulating lipid storage and release in macrophages and foam cells","en":"GOLD3 - Genomics Of Lipid Droplet Biology, Component 8: Lipid droplet-associated proteins regulating lipid storage and release in macrophages and foam cells"},"short":"GOLD3_KRATKY","url":null,"abstract":{"de":"Lipid-associated disorders constitute a major health treat wordlwide. Currently more than one billion individuals are overweight or obese and it is estimated that by 2010 more than 300 million patients will be affected by insulin resistance and type-II diabetes.\r\nThe general aim of GOLD 3 is to elucidate processes that govern the biology of lipid droplets (LD), their synthesis and mobilization under normal and pathological conditions.\r\nThe proposed project will discover genes, proteins, and metabolites involved in the generation and catabolsim of LD in human cells. The characterization of their biochemical function, regulation od their expression, and 3-D structure will reveal currently unknown mechanisms and pathways that control the generation of lipid signalling molecules, energy substrates and membrane components affecting cell tissue function as well as energy homeostasis.","en":"Lipid-associated disorders constitute a major health treat wordlwide. Currently more than one billion individuals are overweight or obese and it is estimated that by 2010 more than 300 million patients will be affected by insulin resistance and type-II diabetes.\r\nThe general aim of GOLD 3 is to elucidate processes that govern the biology of lipid droplets (LD), their synthesis and mobilization under normal and pathological conditions.\r\nThe proposed project will discover genes, proteins, and metabolites involved in the generation and catabolsim of LD in human cells. The characterization of their biochemical function, regulation od their expression, and 3-D structure will reveal currently unknown mechanisms and pathways that control the generation of lipid signalling molecules, energy substrates and membrane components affecting cell tissue function as well as energy homeostasis."},"begin_planned":"2008-12-01T01:00:00+01:00","begin_effective":"2009-02-01T01:00:00+01:00","end_planned":"2011-11-30T01:00:00+01:00","end_effective":"2012-04-30T02:00:00+02:00","assignment":"2009-01-22T11:56:26+01:00","program":73,"subprogram":null,"organization":14013,"category":10,"type":10,"partner_function":2,"manager":51904,"contact":null,"status":2,"research":1,"grant":10,"event":null,"study":null,"language":null,"funders":[152],"funder_projectcode":null,"ethics_committee":null,"edudract_number":null,"persons":["1735-51904-10","1735-58794-11"]},{"id":1714,"title":{"de":"GOLD3 - Genomics Of Lipid Droplet Biology, Component 5: Discovery of lipolytic activities by in vivo proteomic profiling","en":"GOLD3 - Genomics Of Lipid Droplet Biology, Component 5: Discovery of lipolytic activities by in vivo proteomic profiling"},"short":"GOLD3_BIRNER_GRUENBERGER","url":null,"abstract":{"de":"Lipid-associated disorders constitute a major health treat wordlwide. Currently more than one billion individuals are overweight or obese and it is estimated that by 2010 more than 300 million patients will be affected by insulin resistance and type-II diabetes.\r\nThe general aim of GOLD 3 is to elucidate processes that govern the biology of lipid droplets (LD), their synthesis and mobilization under normal and pathological conditions.\r\nThe proposed project will discover genes, proteins, and metabolites involved in the generation and catabolsim of LD in human cells. The characterization of their biochemical function, regulation od their expression, and 3-D structure will reveal currently unknown mechanisms and pathways that control the generation of lipid signalling molecules, energy substrates and membrane components affecting cell tissue function as well as energy homeostasis.","en":"Lipid-associated disorders constitute a major health treat wordlwide. Currently more than one billion individuals are overweight or obese and it is estimated that by 2010 more than 300 million patients will be affected by insulin resistance and type-II diabetes.\r\nThe general aim of GOLD 3 is to elucidate processes that govern the biology of lipid droplets (LD), their synthesis and mobilization under normal and pathological conditions.\r\nThe proposed project will discover genes, proteins, and metabolites involved in the generation and catabolsim of LD in human cells. The characterization of their biochemical function, regulation od their expression, and 3-D structure will reveal currently unknown mechanisms and pathways that control the generation of lipid signalling molecules, energy substrates and membrane components affecting cell tissue function as well as energy homeostasis."},"begin_planned":"2008-12-01T01:00:00+01:00","begin_effective":"2009-02-01T01:00:00+01:00","end_planned":"2011-11-30T01:00:00+01:00","end_effective":"2012-04-30T02:00:00+02:00","assignment":"2009-01-14T12:15:11+01:00","program":73,"subprogram":null,"organization":28394,"category":10,"type":10,"partner_function":2,"manager":58794,"contact":58794,"status":2,"research":2,"grant":10,"event":null,"study":null,"language":null,"funders":[152],"funder_projectcode":null,"ethics_committee":null,"edudract_number":null,"persons":["1714-58794-10"]},{"id":1723,"title":{"de":"Die Rolle von MMP12 und Angiostatin in der humanen Plazentaentwicklung bei Diabetes","en":"Die Rolle von MMP12 und Angiostatin in der humanen Plazentaentwicklung bei Diabetes"},"short":"MMP12 und Angiostatin","url":null,"abstract":{"de":"Die Plazenatentwicklung ist besonders im 1. Schwangerschaftstrimenon kritisch. Trophoblastzellen wandern in den Uterus ein (Invasion), verankern die Plazenta und vergrößern uterine Blutgefäße. Das gesamte Blutgefäßsystem in Plazenta und Uterus expandiert (Angiogenese). Defekte können zu Präeklampsie, fötaler Wachstumsrestriktion oder Fehlgeburt und Pathologien mit erhöhtem Risiko bei Diabetes führen. Vorversuche zeigen, dass Traophoblasten große Mengen des Enzymes MMP12 bilden, das Plasminogen im Serum in Angiostatin spaltet. Diese hemmt Angiogenese und Invasion. In Makrophagen wird MMP12-Synthese durch in Diabetes erhöhte Faktoren (Isulin, TNF-, TGF-) erhöht. In Trophoblasten habe ich Insulin und Glukose als Stimulatoren für MMP12-Bildung identifiziert. Darum wird in diesem Projekt der Effekt von Diabetes im 1. Trimenon auf MMP12-Synthese und der Freisetzung von Angiostatin ermittelt und die Wirkung auf Angiogenese im Uterus und Plazenta sowie auf Trophoblast-Invasion untersucht.","en":"Die Plazenatentwicklung ist besonders im 1. Schwangerschaftstrimenon kritisch. Trophoblastzellen wandern in den Uterus ein (Invasion), verankern die Plazenta und vergrößern uterine Blutgefäße. Das gesamte Blutgefäßsystem in Plazenta und Uterus expandiert (Angiogenese). Defekte können zu Präeklampsie, fötaler Wachstumsrestriktion oder Fehlgeburt und Pathologien mit erhöhtem Risiko bei Diabetes führen. Vorversuche zeigen, dass Traophoblasten große Mengen des Enzymes MMP12 bilden, das Plasminogen im Serum in Angiostatin spaltet. Diese hemmt Angiogenese und Invasion. In Makrophagen wird MMP12-Synthese durch in Diabetes erhöhte Faktoren (Isulin, TNF-, TGF-) erhöht. In Trophoblasten habe ich Insulin und Glukose als Stimulatoren für MMP12-Bildung identifiziert. Darum wird in diesem Projekt der Effekt von Diabetes im 1. Trimenon auf MMP12-Synthese und der Freisetzung von Angiostatin ermittelt und die Wirkung auf Angiogenese im Uterus und Plazenta sowie auf Trophoblast-Invasion untersucht."},"begin_planned":"2009-02-01T01:00:00+01:00","begin_effective":"2009-02-01T01:00:00+01:00","end_planned":"2011-01-31T01:00:00+01:00","end_effective":"2011-07-31T02:00:00+02:00","assignment":"2009-01-16T14:13:41+01:00","program":79,"subprogram":null,"organization":14038,"category":10,"type":10,"partner_function":4,"manager":50674,"contact":50674,"status":2,"research":1,"grant":10,"event":null,"study":null,"language":null,"funders":[12],"funder_projectcode":null,"ethics_committee":null,"edudract_number":null,"persons":["1723-50674-10"]},{"id":1722,"title":{"de":"Determining the Hierarchy of EMTRs in Malignant Melanoma","en":"Determining the Hierarchy of EMTRs in Malignant Melanoma"},"short":"DETERMINING_HIERARCHY_EMTR_MELANOMA","url":null,"abstract":{"de":"Epithelial-mesenchymal transition (EMT) is a hallmark of cellular transformation in solid tumors. A similar process is thought to be relevant for melanomgenesis. The exact mechanisms how this is accomplished with respect to stage specific effects of epilthelial-mesenchymal transcriptional regulation, however, are unknown for many tumor entities and melanoma in particular. \r\nThe intent of this project is to decipher targets of EMT inducing regulators at the transcriptional level as exemplified by modulation of cadherins through hepatocyte growth factor (HGF), an important growth factor in melanomagenesis. Our previous data show that the effect of HGF on epithelial-mesenchymal transcriptional regulators (EMTRs) is stage-dependent in melanoma cell lines. Based on these observations we want to pinpoint EMTRs specific binding to E-boxes in cadherins, investigate on HGF-mediated regulation of Snail and Slug and study overexpression of Slug and Twist in melanoma cell lines. We expect to uncover the hierachical sequence of EMTRs activation in early versus late stage melanomas, the preferential binding of EMRTs to cadherins and in vitro and in vivo effects of over-expressed or down-regulated EMRTs. The following hypothesis:\r\n\"Hierachy of epithelial-mesenchymal transcriptional regulators in malignant melanoma\"\r\nwill be tested in two specific aims:\r\n*Continuing investigations on E-box binding EMRTs and the functional effects of Slug and Twist in melanocytic cells \r\n*Scrutinizing HGF mediated modulation of Snail, Slug and Twist through regulation by NF-kB and GSK -3ß.","en":"Epithelial-mesenchymal transition (EMT) is a hallmark of cellular transformation in solid tumors. A similar process is thought to be relevant for melanomgenesis. The exact mechanisms how this is accomplished with respect to stage specific effects of epilthelial-mesenchymal transcriptional regulation, however, are unknown for many tumor entities and melanoma in particular. \r\nThe intent of this project is to decipher targets of EMT inducing regulators at the transcriptional level as exemplified by modulation of cadherins through hepatocyte growth factor (HGF), an important growth factor in melanomagenesis. Our previous data show that the effect of HGF on epithelial-mesenchymal transcriptional regulators (EMTRs) is stage-dependent in melanoma cell lines. Based on these observations we want to pinpoint EMTRs specific binding to E-boxes in cadherins, investigate on HGF-mediated regulation of Snail and Slug and study overexpression of Slug and Twist in melanoma cell lines. We expect to uncover the hierachical sequence of EMTRs activation in early versus late stage melanomas, the preferential binding of EMRTs to cadherins and in vitro and in vivo effects of over-expressed or down-regulated EMRTs. The following hypothesis:\r\n\"Hierachy of epithelial-mesenchymal transcriptional regulators in malignant melanoma\"\r\nwill be tested in two specific aims:\r\n*Continuing investigations on E-box binding EMRTs and the functional effects of Slug and Twist in melanocytic cells \r\n*Scrutinizing HGF mediated modulation of Snail, Slug and Twist through regulation by NF-kB and GSK -3ß."},"begin_planned":"2008-08-01T02:00:00+02:00","begin_effective":"2009-01-15T01:00:00+01:00","end_planned":"2009-07-31T02:00:00+02:00","end_effective":"2011-01-14T01:00:00+01:00","assignment":"2009-01-16T14:06:24+01:00","program":72,"subprogram":null,"organization":14047,"category":10,"type":10,"partner_function":4,"manager":53662,"contact":53662,"status":2,"research":5,"grant":10,"event":null,"study":null,"language":null,"funders":[9],"funder_projectcode":"P21156","ethics_committee":null,"edudract_number":null,"persons":["1722-53662-10"]},{"id":1759,"title":{"de":"Integration der Gesundheitsförderung in die Gesundheitsberichterstattung - Schwerpunkt Psychosoziale Gesundheit","en":"Integration der Gesundheitsförderung in die Gesundheitsberichterstattung -Schwerpunkt Psychosoziale Gesundheit"},"short":"Gesundheitsförderung","url":null,"abstract":{"de":"Psychische Gesundheit („mental health“) ist ein integraler Bestandteil des bio-psycho-sozialen Gesundheitsbegriffes der Weltgesundheitsorganisation (WHO), „there is no health without mental health“ (WHO, 2007).\r\nPsychosoziale Beeinträchtigungen tragen erheblich zur gesamten Krankheitslast bei. Sie haben einen deutlichen ökonomischen und gesellschaftlichen Impact. Gemäß WHO erkranken etwa 25 % der Bevölkerung im Laufe ihres Lebens an mindestens einer psychischen Störung oder Verhaltensstörung. Es herrscht eine hohe Komorbidität zwischen psychosozialen Gesundheitsbeeinträchtigungen, psychischen Erkrankungen und körperlichen Leiden. \r\nDie Förderung psychosozialer Gesundheit umfasst alle Strategien, die einen positiven Impact auf die psychische, soziale und indirekt auch auf die biologische Gesundheit ausüben\r\nGesundheitsberichterstattung zielt darauf ab, epidemiologische und medizinalstatistische Daten so aufzuarbeiten, dass sie für die Gesundheitspolitik, die Gesundheitsförderung und die Gesundheitssystemgestaltung nutzbar gemacht werden können. Die Erfassung der psychosozialen Gesundheit hat bis jetzt kaum Niederschlag in der Gesundheitsberichterstattung gefunden\r\n\r\nKurzkonzept des Projekts:\r\nSchritt 1) Erhebung des Ist-Zustandes\r\nSchritt 2) Literaturrecherche\r\nSchritt 3) Sekundäranalyse des existierenden Datenmaterials \r\nSchritt 4) Einrichtung eines Expertinnen und Experten Panels\r\nSchritt 5) Erstellung eines standardisierten Instruments zur Erhebung der psychosozialen Gesundheit auf Community Level\r\n","en":"Psychische Gesundheit („mental health“) ist ein integraler Bestandteil des bio-psycho-sozialen Gesundheitsbegriffes der Weltgesundheitsorganisation (WHO), „there is no health without mental health“ (WHO, 2007).\r\nPsychosoziale Beeinträchtigungen tragen erheblich zur gesamten Krankheitslast bei. Sie haben einen deutlichen ökonomischen und gesellschaftlichen Impact. Gemäß WHO erkranken etwa 25 % der Bevölkerung im Laufe ihres Lebens an mindestens einer psychischen Störung oder Verhaltensstörung. Es herrscht eine hohe Komorbidität zwischen psychosozialen Gesundheitsbeeinträchtigungen, psychischen Erkrankungen und körperlichen Leiden. \r\nDie Förderung psychosozialer Gesundheit umfasst alle Strategien, die einen positiven Impact auf die psychische, soziale und indirekt auch auf die biologische Gesundheit ausüben\r\nGesundheitsberichterstattung zielt darauf ab, epidemiologische und medizinalstatistische Daten so aufzuarbeiten, dass sie für die Gesundheitspolitik, die Gesundheitsförderung und die Gesundheitssystemgestaltung nutzbar gemacht werden können. Die Erfassung der psychosozialen Gesundheit hat bis jetzt kaum Niederschlag in der Gesundheitsberichterstattung gefunden\r\n\r\nKurzkonzept des Projekts:\r\nSchritt 1) Erhebung des Ist-Zustandes\r\nSchritt 2) Literaturrecherche\r\nSchritt 3) Sekundäranalyse des existierenden Datenmaterials \r\nSchritt 4) Einrichtung eines Expertinnen und Experten Panels\r\nSchritt 5) Erstellung eines standardisierten Instruments zur Erhebung der psychosozialen Gesundheit auf Community Level\r\n"},"begin_planned":"2009-01-01T01:00:00+01:00","begin_effective":"2009-01-01T01:00:00+01:00","end_planned":"2009-12-31T01:00:00+01:00","end_effective":"2009-12-31T01:00:00+01:00","assignment":"2009-03-02T17:12:37+01:00","program":null,"subprogram":null,"organization":14024,"category":10,"type":10,"partner_function":4,"manager":null,"contact":null,"status":2,"research":5,"grant":10,"event":null,"study":null,"language":null,"funders":[70],"funder_projectcode":null,"ethics_committee":null,"edudract_number":null,"persons":["1759-53649-12","1759-51845-12"]},{"id":1734,"title":{"de":"Verkalkung von Gefäßen und Knochen bei NierentransplantationspatientInnen [Regulierung der Kalzifizierung bei NierentransplantationspatientInnen]","en":"Verkalkung von Gefäßen und Knochen bei NierentransplantationspatientInnen [Regulierung der Kalzifizierung bei NierentransplantationspatientInnen]"},"short":"Verkalkung bei Nierentransplantationen","url":null,"abstract":{"de":"Kalzifizierung tritt physiologisch im Knochen und pathophysiologisch im Gefäßsystem auf. Kardiovaskuläre Erkrankungen sind eine Haupt-Todesursache von Nierenerkrankten und sind entscheidend für die Durchführbarkeit von Nierentransplantationen (RTX). Das derezeitige Wissen um die Regulation der Kalzifizierung in Knochen und Gefäßsystem bei RTX-Patienten ist fragmentarisch.\r\n\r\nDiese offene, kontrollierte, monozentrische Studie untersucht die Regulation der Kalzifizierung im Knochen- und Gefäßsystem bei PatientInnen mit RTX.\r\nUnsere Fragestellung zielt auf Unterschiede der Expressionslevels von Regulatoren der Kalzifizierung in beiden Gewebstypen und im Vergleich von athero- und mediasklerotischen Gefäßen.\r\nWir erwarten uns Einblick in Kalzifizierungsmechanismen und mögliche klinische Aspekte für Diagnose und Therapie bei diesen HochrisikopatientInnen.","en":"Kalzifizierung tritt physiologisch im Knochen und pathophysiologisch im Gefäßsystem auf. Kardiovaskuläre Erkrankungen sind eine Haupt-Todesursache von Nierenerkrankten und sind entscheidend für die Durchführbarkeit von Nierentransplantationen (RTX). Das derezeitige Wissen um die Regulation der Kalzifizierung in Knochen und Gefäßsystem bei RTX-Patienten ist fragmentarisch.\r\n\r\nDiese offene, kontrollierte, monozentrische Studie untersucht die Regulation der Kalzifizierung im Knochen- und Gefäßsystem bei PatientInnen mit RTX.\r\nUnsere Fragestellung zielt auf Unterschiede der Expressionslevels von Regulatoren der Kalzifizierung in beiden Gewebstypen und im Vergleich von athero- und mediasklerotischen Gefäßen.\r\nWir erwarten uns Einblick in Kalzifizierungsmechanismen und mögliche klinische Aspekte für Diagnose und Therapie bei diesen HochrisikopatientInnen."},"begin_planned":"2009-01-01T01:00:00+01:00","begin_effective":"2009-01-01T01:00:00+01:00","end_planned":"2011-12-31T01:00:00+01:00","end_effective":"2012-12-31T01:00:00+01:00","assignment":"2009-01-21T15:49:20+01:00","program":79,"subprogram":null,"organization":14073,"category":10,"type":10,"partner_function":4,"manager":51982,"contact":51982,"status":2,"research":2,"grant":10,"event":null,"study":null,"language":null,"funders":[12],"funder_projectcode":null,"ethics_committee":null,"edudract_number":null,"persons":["1734-51982-10","1734-57544-12"]},{"id":1725,"title":{"de":"Role of T regulatory cells in polymorphic light eruption","en":"Role of T regulatory cells in polymorphic light eruption"},"short":"polymorphic light eruption","url":null,"abstract":{"de":"Die polymorphe Lichtdermatose (PLD- \"Sonnenallergie\"), deren Prävalenz (mit bis zu 20%) vor allem bei jungen Frauen außerordentlich hoch ist, ist durch an sonnenexponierten Körperstellen auftretende, stark juckende Hautveränderungen gekennzeichnet. Die Ätiopathogenese der PLD ist unbekannt, eine Störung der UV-induzierten Immunsuppression mit Immunreaktionen gegen Photoneoantigene der Haut wird vermutet. Bei der Immunsuppression nach UV-EInwirkung kommt den regulatorischen T-Zellen (CD4+CD25+FoxP3+) (Tregs), einer Subpoulation der T-Helfer Zellen, eine bedeutende Rolle zu.\r\nIm vorliegenden Projekt soll die Hypothese geprüft werden, dass Tregs von PLD-Patienten pathogenetisch bedeutsam im Jahresverlauf abnormal fluktuierende Spiegel und Funktionen aufweisen, welche möglicherweise durch Photohardening (UV-Abhärtung) normalisierbar sind. Aus einem besseren Verständnis der Pathogenese der PLD könnten möglicherweise Ansätze für neue therapeutische Strategien resultieren.","en":"Die polymorphe Lichtdermatose (PLD- \"Sonnenallergie\"), deren Prävalenz (mit bis zu 20%) vor allem bei jungen Frauen außerordentlich hoch ist, ist durch an sonnenexponierten Körperstellen auftretende, stark juckende Hautveränderungen gekennzeichnet. Die Ätiopathogenese der PLD ist unbekannt, eine Störung der UV-induzierten Immunsuppression mit Immunreaktionen gegen Photoneoantigene der Haut wird vermutet. Bei der Immunsuppression nach UV-EInwirkung kommt den regulatorischen T-Zellen (CD4+CD25+FoxP3+) (Tregs), einer Subpoulation der T-Helfer Zellen, eine bedeutende Rolle zu.\r\nIm vorliegenden Projekt soll die Hypothese geprüft werden, dass Tregs von PLD-Patienten pathogenetisch bedeutsam im Jahresverlauf abnormal fluktuierende Spiegel und Funktionen aufweisen, welche möglicherweise durch Photohardening (UV-Abhärtung) normalisierbar sind. Aus einem besseren Verständnis der Pathogenese der PLD könnten möglicherweise Ansätze für neue therapeutische Strategien resultieren."},"begin_planned":"2009-01-01T01:00:00+01:00","begin_effective":"2009-01-01T01:00:00+01:00","end_planned":"2010-12-31T01:00:00+01:00","end_effective":"2011-11-30T01:00:00+01:00","assignment":"2009-01-16T14:41:21+01:00","program":79,"subprogram":null,"organization":14047,"category":10,"type":10,"partner_function":4,"manager":51618,"contact":51618,"status":2,"research":2,"grant":10,"event":null,"study":null,"language":null,"funders":[12],"funder_projectcode":null,"ethics_committee":null,"edudract_number":null,"persons":["1725-54011-12","1725-51618-10"]},{"id":1671,"title":{"de":"Nachweis antibiotikarestistenter Escherichia coli-Stämme aus Klärschlamm unter Berücksichtigung der verschiedenen Klärschlammbehandlungsverfahren","en":"Nachweis antibiotikarestistenter Escherichia coli-Stämme aus Klärschlamm unter Berücksichtigung der verschiedenen Klärschlammbehandlungsverfahren"},"short":"Escherichia coli-Stämme aus Klärschlamm ","url":null,"abstract":{"de":"Die Ausbreitung resistenter Bakterien und antibiotisch wirksamer Substanzen aus Klärschlamm in die Umwelt ist derzeit nur schwer abschätzbar.\r\nIn der vorliegenden Studie sollten antibiotikaresistente Bakterien im Zusammenhang mit unterschiedlichen Behandlungs- und Hygienisierungsverfahren von Klärschlamm untersucht werden. Dabei sollten jene unterschiedlichen Verfahren verglichen werden bei welchen einerseits bei Einhaltung der richtigen Prozessbedingungen eine Entseuchung des Klärschlammes sichergestellt wird und andererseits die konventionellen Schlammbehandlungsverfahren, z.B. die anaerobe mesophile Faulung und die aerobe Stabilisierung.","en":"Die Ausbreitung resistenter Bakterien und antibiotisch wirksamer Substanzen aus Klärschlamm in die Umwelt ist derzeit nur schwer abschätzbar.\r\nIn der vorliegenden Studie sollten antibiotikaresistente Bakterien im Zusammenhang mit unterschiedlichen Behandlungs- und Hygienisierungsverfahren von Klärschlamm untersucht werden. Dabei sollten jene unterschiedlichen Verfahren verglichen werden bei welchen einerseits bei Einhaltung der richtigen Prozessbedingungen eine Entseuchung des Klärschlammes sichergestellt wird und andererseits die konventionellen Schlammbehandlungsverfahren, z.B. die anaerobe mesophile Faulung und die aerobe Stabilisierung."},"begin_planned":"2009-01-01T01:00:00+01:00","begin_effective":"2009-01-01T01:00:00+01:00","end_planned":"2009-12-31T01:00:00+01:00","end_effective":"2010-01-31T01:00:00+01:00","assignment":"2008-12-04T12:26:09+01:00","program":null,"subprogram":"Fördergeber Land Steiermark Fachabteilung 19D","organization":14023,"category":10,"type":10,"partner_function":4,"manager":51674,"contact":51674,"status":2,"research":2,"grant":10,"event":null,"study":null,"language":null,"funders":[135],"funder_projectcode":null,"ethics_committee":null,"edudract_number":null,"persons":["1671-51674-10"]},{"id":1706,"title":{"de":"Modulation des sensorimotorischen Kortex mittels anhaltender mechanischer und peripherer magnetischer Stimulation - Effektivität und therapeutisches Potential","en":"Modulation of sensorimotor cortex by sustained mechanical and peripheral magnetic stimulation - effectiveness and therapeutical potential"},"short":"SENSORIMOTOR CORTEX_OENB2008","url":null,"abstract":{"de":"Im vorliegenden Projektvorschlag soll überprüft werden, ob sich mittels afferenter Stimulation im Bereich von Finger und Hand poststimulatorische adaptive Effekte im sensomotorischen Kortex anregen lassen. Da solcherart neuoplastische Effekte mit einer erhöhten kortikospinalen Erregbarkeit einhergehen, eignen sich hier nichtinvasive Methoden wie TMS und fMRI für den Nachweis. Im Rahmen dieses Projekts sollen zwei Arten der afferenten Stimulation zur Anwendung kommen, die periphere Magnetstimulation und die biomechanische Stimulation. Bezüglich der Stimulationsfrequenz gibt es Hinweise dass eine Frequenz um 25 Hz optimal sein könnte (kortikale Resonanz), daher sollen hier 10 und 25 Hz getestet werden. Ziel des Projekts ist es die Post-Stimulus-Effekte bezüglich ihrer Effektstärke und Anhaltedauer zu charakterisieren und hinblicklich ihrer zugrunde liegenden Mechanismen (unmasking, LTP) zu diskutieren. Ein weiters Ziel ist es die Ergebnisse für die Neurorehabilitation nutzbar zu machen.","en":"The proposed research examines the hypothesis that sustained somatosensory stimulation induces post-stimulus adaptive changes in primary motor cortex of healthy subjects. As such changes are associated with increased corticospinal excitability and reorganization of cortical networks, non-invasive assessment tools like transcranial magnetic stimulation (TMS) and functional magnetic resonance imaging (fMRI) are suited to evaluate the stimulation effects. Two types of sensory stimulation will be tested and compared here, repetitive peripheral magnetic stimulation (RPMS) of hand muscles and whole-hand mechanical stimulation (MSTIM). The research strategy employs a series of experiments to quantify the adaptive changes following stimulation protocols with different parameters. Specifically, we are interested into stimuli to effectively modulate the motor cortex, and into the reliability of the two assessment tools to quantify the post-stimulus effects. These experimental series will provide a fundamental scientific basis for better understanding how sustained sensory stimulation modulates central motor controlling structures and will help to evaluate the potential clinical benefit from the proposed stimulation techiques."},"begin_planned":"2009-01-01T01:00:00+01:00","begin_effective":"2009-01-01T01:00:00+01:00","end_planned":"2010-12-31T01:00:00+01:00","end_effective":"2011-06-30T02:00:00+02:00","assignment":"2008-12-22T11:08:25+01:00","program":79,"subprogram":null,"organization":14010,"category":10,"type":10,"partner_function":4,"manager":51814,"contact":51814,"status":2,"research":1,"grant":10,"event":null,"study":null,"language":null,"funders":[12],"funder_projectcode":null,"ethics_committee":null,"edudract_number":null,"persons":["1706-51814-10"]},{"id":1702,"title":{"de":"Identification of genes associated with autism spectrum disorder","en":"Identification of genes associated with autism spectrum disorder"},"short":"AUTISM SPECTRUM DISORDER","url":null,"abstract":{"de":"Das \"Autismus-Spektrum\" umfasst insbesondere den frühkindlichen Autismus, den atypischen Autismus und das Asperger-Syndrom. Aufgrund der hohen Konkordanzraten eineiiger Zwillinge geht die Forschung in der Zwischenzeit davon aus, dass Autismus wesentlich auf genetische Ursachen zurückzuführen ist. Durch die in den letzten jahren erfolgte Entwicklung der \"vergleichenden genomischen Hybridisierung (CGH)\" und der sogenannten \"Microarray Analyse\" wird statt nach einzelnen veränderten Bausteinen im Erbgut der Probanden zu suchen, nach ganzen Abschnitten gefahndet, die entweder vollständig fehlen oder aber in doppelter Ausführung vorliegen. Dieser als CNV-Methode (Variationen in der Kopienzahl) bezeichnete Ansatz führte in den letzten beiden Jahren zu ungeahnten Variationen im menschlichen Genom. Unser Konzept im vorliegenden Forschungsantrag sieht vor, 70 bereits gut diagnostizierte Autismus PatientInnen mittels \"state-of-the-art\" Methoden auf Phänotyp-spezifische CNVs zu untersuchen.","en":"Das \"Autismus-Spektrum\" umfasst insbesondere den frühkindlichen Autismus, den atypischen Autismus und das Asperger-Syndrom. Aufgrund der hohen Konkordanzraten eineiiger Zwillinge geht die Forschung in der Zwischenzeit davon aus, dass Autismus wesentlich auf genetische Ursachen zurückzuführen ist. Durch die in den letzten jahren erfolgte Entwicklung der \"vergleichenden genomischen Hybridisierung (CGH)\" und der sogenannten \"Microarray Analyse\" wird statt nach einzelnen veränderten Bausteinen im Erbgut der Probanden zu suchen, nach ganzen Abschnitten gefahndet, die entweder vollständig fehlen oder aber in doppelter Ausführung vorliegen. Dieser als CNV-Methode (Variationen in der Kopienzahl) bezeichnete Ansatz führte in den letzten beiden Jahren zu ungeahnten Variationen im menschlichen Genom. Unser Konzept im vorliegenden Forschungsantrag sieht vor, 70 bereits gut diagnostizierte Autismus PatientInnen mittels \"state-of-the-art\" Methoden auf Phänotyp-spezifische CNVs zu untersuchen."},"begin_planned":"2009-01-01T01:00:00+01:00","begin_effective":"2009-01-01T01:00:00+01:00","end_planned":"2010-12-31T01:00:00+01:00","end_effective":"2011-06-30T02:00:00+02:00","assignment":"2008-12-15T15:19:50+01:00","program":79,"subprogram":null,"organization":14021,"category":10,"type":10,"partner_function":4,"manager":51996,"contact":null,"status":2,"research":1,"grant":10,"event":null,"study":null,"language":null,"funders":[12],"funder_projectcode":null,"ethics_committee":null,"edudract_number":null,"persons":["1702-51996-10"]},{"id":1957,"title":{"de":"Genetics of the Dopaminergic System and Smoking Behavior","en":"Genetics of the Dopaminergic System and Smoking Behavior"},"short":"Genetics of the Dopaminergic System","url":null,"abstract":{"de":null,"en":null},"begin_planned":"2009-01-01T01:00:00+01:00","begin_effective":"2009-01-01T01:00:00+01:00","end_planned":"2010-12-30T01:00:00+01:00","end_effective":"2010-12-30T01:00:00+01:00","assignment":"2009-10-23T12:55:40+02:00","program":null,"subprogram":null,"organization":14028,"category":10,"type":10,"partner_function":4,"manager":50910,"contact":50910,"status":2,"research":2,"grant":10,"event":null,"study":null,"language":null,"funders":[135],"funder_projectcode":null,"ethics_committee":null,"edudract_number":null,"persons":["1957-50910-10"]},{"id":1721,"title":{"de":"Influence of Resveratrol, Quercetin-dihydrate und Seleno-L-Methoionine an Matrix Metalloproteinases and RANKL Levels in Human Osteoarthritis Rheumatoid Arthritis Synovial Fluids","en":"Influence of Resveratrol, Quercetin-dihydrate und Seleno-L-Methoionine an Matrix Metalloproteinases and RANKL Levels in Human Osteoarthritis Rheumatoid Arthritis Synovial Fluids"},"short":"Metalloproteinases and RANKL Levels ","url":null,"abstract":{"de":"Osteoarthritis (OA) is the most prevalent disorder of the musculoskeletal system and has a very high socioeconomic impact. Current treatments for Osteoarthritis are only symptomatic, because they do not act on the causes of Arthritis and do not stop the progression of the disease. This study is designed to investigate the effect of Resveratrol, Quercetin, and Selenium on special inflammation enzymes and factors in human synovial fluid. \r\nEspecially Resveratrol is known as a potent specific inhibitor of inflammation, but its potency has not been tested on human synovial fluid. If the protective potency on Osteoarthritis is similar to the results of animal experiments, it would be an enormous effort. Previous studies indicate that elevated levels of matrix metalloproteinases (MMPs) and receptor activator of nuclear factor NFkB ligand (RANKL) play an important role in cartilage degeneration in OA Rheumatic Arthritis (RA) and Psoriatic Arthritis (PsA) [1, 2]. \r\nThis study should be undertaken to define a possible influence of Resveratrol compared to other antioxidants like Quercetin and Selenium on synovial fluid and these factors. A close interaction between clinicians and basic scientists is necessary because of the combination of analytical, functional and molecular methods. \r\n","en":"Osteoarthritis (OA) is the most prevalent disorder of the musculoskeletal system and has a very high socioeconomic impact. Current treatments for Osteoarthritis are only symptomatic, because they do not act on the causes of Arthritis and do not stop the progression of the disease. This study is designed to investigate the effect of Resveratrol, Quercetin, and Selenium on special inflammation enzymes and factors in human synovial fluid. \r\nEspecially Resveratrol is known as a potent specific inhibitor of inflammation, but its potency has not been tested on human synovial fluid. If the protective potency on Osteoarthritis is similar to the results of animal experiments, it would be an enormous effort. Previous studies indicate that elevated levels of matrix metalloproteinases (MMPs) and receptor activator of nuclear factor NFkB ligand (RANKL) play an important role in cartilage degeneration in OA Rheumatic Arthritis (RA) and Psoriatic Arthritis (PsA) [1, 2]. \r\nThis study should be undertaken to define a possible influence of Resveratrol compared to other antioxidants like Quercetin and Selenium on synovial fluid and these factors. A close interaction between clinicians and basic scientists is necessary because of the combination of analytical, functional and molecular methods. \r\n"},"begin_planned":"2009-01-01T01:00:00+01:00","begin_effective":"2009-01-01T01:00:00+01:00","end_planned":"2009-12-31T01:00:00+01:00","end_effective":"2009-12-31T01:00:00+01:00","assignment":"2009-01-15T11:27:46+01:00","program":null,"subprogram":null,"organization":14052,"category":10,"type":10,"partner_function":4,"manager":null,"contact":null,"status":2,"research":1,"grant":10,"event":null,"study":null,"language":null,"funders":[],"funder_projectcode":null,"ethics_committee":null,"edudract_number":null,"persons":["1721-50696-12","1721-57343-12","1721-50826-12"]},{"id":1543,"title":{"de":"Expression und Lokalisierung der Endothel Lipase in stabilen und unstabilen atherosklerotischen Plaques","en":"Expression and localization of endothelial lipase in stable and unstable atherosclerotic plaques"},"short":"EXPRESS_LOKALIS_ENDOTHEL_LIPASE","url":null,"abstract":{"de":"Atherosklerose im Bereich der Karotiden ist Hauptverursacher des Schlaganfalles, einer der häufigsten Invaliditäts- und Todesursachen in den westlichen Industrieländern. Das Auftreten von neurologischen Symptomen bei betroffenen Patienten geht mit der Destabilisierung der atherosklerotischen Plaques einher. Da die Endothel Lipase in den Plaque-assoziierten Zellen exprimiert wird, wollen wir im Rahmen des beantragten Projektes untersuchen ob sich die Expressionsrate und die zellspezifische Lokalisierung der Endothel Lipase zwischen stabilen und unstabilen atherosklerotischen Plaques von Patienten nach operativer Endarterektomie unterscheidet. Die Ergebnisse dieser Studie versprechen neue Erkenntnisse über die Rolle von Endothel Lipase in der Entwicklung und Destabilisierung von karotidalen atherosklerotischen Plaques und stellen die Basis für die Entwicklung neuer Medikamente zur Prävention von Plaque-Destabilisierung dar.","en":"Atherosklerose im Bereich der Karotiden ist Hauptverursacher des Schlaganfalles, einer der häufigsten Invaliditäts- und Todesursachen in den westlichen Industrieländern. Das Auftreten von neurologischen Symptomen bei betroffenen Patienten geht mit der Destabilisierung der atherosklerotischen Plaques einher. Da die Endothel Lipase in den Plaque-assoziierten Zellen exprimiert wird, wollen wir im Rahmen des beantragten Projektes untersuchen ob sich die Expressionsrate und die zellspezifische Lokalisierung der Endothel Lipase zwischen stabilen und unstabilen atherosklerotischen Plaques von Patienten nach operativer Endarterektomie unterscheidet. Die Ergebnisse dieser Studie versprechen neue Erkenntnisse über die Rolle von Endothel Lipase in der Entwicklung und Destabilisierung von karotidalen atherosklerotischen Plaques und stellen die Basis für die Entwicklung neuer Medikamente zur Prävention von Plaque-Destabilisierung dar."},"begin_planned":"2008-10-01T02:00:00+02:00","begin_effective":"2008-10-01T02:00:00+02:00","end_planned":"2011-09-30T02:00:00+02:00","end_effective":"2011-09-30T02:00:00+02:00","assignment":"2008-05-29T11:09:47+02:00","program":79,"subprogram":null,"organization":14013,"category":10,"type":10,"partner_function":4,"manager":51988,"contact":51988,"status":2,"research":1,"grant":10,"event":null,"study":null,"language":null,"funders":[12],"funder_projectcode":null,"ethics_committee":null,"edudract_number":null,"persons":["1543-51988-10"]},{"id":2161,"title":{"de":"BM.W_Fa-Zusatzfinanzierung 7. RP zu EU Projekt \"HEALTH-F5-2008-22916\" (SPIDIA)","en":"BM.W_Fa-funding to the 7th EU FP \"HEALTH-F5-2008-22916\" (SPIDIA)"},"short":"BM.W_Fa Zusatzfinanzierung SPIDIA","url":null,"abstract":{"de":null,"en":null},"begin_planned":"2008-10-01T02:00:00+02:00","begin_effective":"2008-10-01T02:00:00+02:00","end_planned":"2012-09-30T02:00:00+02:00","end_effective":"2012-09-30T02:00:00+02:00","assignment":"2010-03-15T13:01:21+01:00","program":90,"subprogram":null,"organization":14020,"category":10,"type":10,"partner_function":4,"manager":51663,"contact":51663,"status":2,"research":1,"grant":10,"event":null,"study":null,"language":null,"funders":[25],"funder_projectcode":null,"ethics_committee":null,"edudract_number":null,"persons":["2161-51663-10"]},{"id":1577,"title":{"de":"Identification of specific endothelial binding-sites for inflammatory carbamylated low-density lipoproteins","en":"Identification of specific endothelial binding-sites for inflammatory carbamylated low-density lipoproteins"},"short":"CARBAMYL_LDL_FWF08","url":null,"abstract":{"de":"In renal disease, elevated levels of urea lead to an increased concentration of cyanate that reacts irreversible with amino groups of proteins through carbamylation reactions. High concentrations of carbamylated low-density-lipoproteins (cLDL) have recently been reported to accumulate in plasma of pateints with chronic renal failure, indicating that cLDL is by far the most abundant modified LDL found in human plasa. Of importance, carbamylated proteins may also be formed directly at sites of inflammation - even in the absence of renal disease- via the phagocyte derived inflammatory mediator myeloperoxidase (MPO). Active MPO is present in human atherosclerotic lesion material and has been shown to bind to low- and high-density lipoproteins. Thus, it can be assumed that MPO derived cyanate contributes to lipoprotein carbamylation at sites of inflammation. Recent clinical studies demonstrated that carbamylated proteins predict increased risk of coronary artery disease, future myocardial infarction, stroke and death.\r\n\r\nNo endothelial receptors of binding proteins that might trigger the potent pro-atherosclerotic effects of carbamylated LDL have yet been identified. Therefore, the aim of the proposed project is to identify endothelial receptors for carbamylated LDL and to systemically examine the impact of carbamylated LDL on the expression of inflammatory genes in human derived vascular endothelial cells.","en":"In renal disease, elevated levels of urea lead to an increased concentration of cyanate that reacts irreversible with amino groups of proteins through carbamylation reactions. High concentrations of carbamylated low-density-lipoproteins (cLDL) have recently been reported to accumulate in plasma of pateints with chronic renal failure, indicating that cLDL is by far the most abundant modified LDL found in human plasa. Of importance, carbamylated proteins may also be formed directly at sites of inflammation - even in the absence of renal disease- via the phagocyte derived inflammatory mediator myeloperoxidase (MPO). Active MPO is present in human atherosclerotic lesion material and has been shown to bind to low- and high-density lipoproteins. Thus, it can be assumed that MPO derived cyanate contributes to lipoprotein carbamylation at sites of inflammation. Recent clinical studies demonstrated that carbamylated proteins predict increased risk of coronary artery disease, future myocardial infarction, stroke and death.\r\n\r\nNo endothelial receptors of binding proteins that might trigger the potent pro-atherosclerotic effects of carbamylated LDL have yet been identified. Therefore, the aim of the proposed project is to identify endothelial receptors for carbamylated LDL and to systemically examine the impact of carbamylated LDL on the expression of inflammatory genes in human derived vascular endothelial cells."},"begin_planned":"2008-10-01T02:00:00+02:00","begin_effective":"2008-10-01T02:00:00+02:00","end_planned":"2011-09-30T02:00:00+02:00","end_effective":"2013-09-30T02:00:00+02:00","assignment":"2008-07-14T14:41:55+02:00","program":72,"subprogram":null,"organization":14022,"category":10,"type":10,"partner_function":4,"manager":53252,"contact":53252,"status":2,"research":1,"grant":10,"event":null,"study":null,"language":null,"funders":[9],"funder_projectcode":"P21004","ethics_committee":null,"edudract_number":null,"persons":["1577-53252-10"]},{"id":1936,"title":{"de":"CII-AT-0042-04-0809 - Medical Imaging & Medical Information Processing","en":"CII-AT-0042-04-0809 - Medical Imaging & Medical Information Processing"},"short":"CEEPUS Medical Imaging","url":null,"abstract":{"de":null,"en":null},"begin_planned":"2008-10-01T02:00:00+02:00","begin_effective":"2008-10-01T02:00:00+02:00","end_planned":"2009-09-30T02:00:00+02:00","end_effective":"2009-09-30T02:00:00+02:00","assignment":null,"program":null,"subprogram":null,"organization":14106,"category":10,"type":10,"partner_function":2,"manager":51913,"contact":null,"status":2,"research":2,"grant":10,"event":null,"study":null,"language":null,"funders":[],"funder_projectcode":null,"ethics_committee":null,"edudract_number":null,"persons":["1936-83445-12","1936-51824-12","1936-51709-12","1936-51913-10"]}]}